Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of “Buy” by Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $36.50.

Several research firms recently issued reports on BCAX. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research note on Thursday, March 27th. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a report on Thursday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, HC Wainwright lowered their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, April 7th.

Bicara Therapeutics Trading Up 6.1 %

NASDAQ BCAX opened at $10.77 on Friday. The business’s fifty day moving average is $12.76 and its 200-day moving average is $16.82. Bicara Therapeutics has a one year low of $8.91 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Equities analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of BCAX. Geode Capital Management LLC bought a new position in Bicara Therapeutics in the third quarter worth about $1,239,000. FMR LLC acquired a new stake in Bicara Therapeutics in the third quarter valued at approximately $57,913,000. Wellington Management Group LLP purchased a new position in Bicara Therapeutics in the third quarter worth $19,458,000. Point72 Asset Management L.P. acquired a new position in shares of Bicara Therapeutics during the third quarter worth $9,474,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at $30,329,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.